Patents by Inventor Pei-Yong Shi

Pei-Yong Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210145907
    Abstract: The present disclosure involves a composition and method of treatment of glioblastoma, using ZIKA virus.
    Type: Application
    Filed: June 11, 2018
    Publication date: May 20, 2021
    Inventors: Michael Diamond, Milan Chheda, Jeremy Rich, Pei-Yong Shi, Zhe Zhu, Matthew Gorman
  • Publication number: 20210047329
    Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 18, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jia Zhou, Pei-Yong Shi, Jimin Xu, Xuping Xie
  • Publication number: 20200197505
    Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.
    Type: Application
    Filed: February 14, 2018
    Publication date: June 25, 2020
    Inventors: Pei-Yong SHI, Xuping XIE, Chao SHAN
  • Patent number: 10533997
    Abstract: Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 14, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Pei-Yong Shi, Chao Shan, Xuping Xie
  • Publication number: 20190293660
    Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Applicants: Health Research, Inc., The Board of Regents of The University Of Texas System
    Inventors: Susan J. WONG, Pei-Yong SHI
  • Patent number: 10317413
    Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: June 11, 2019
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, HEALTH RESEARCH, INCORPORATED
    Inventors: Susan J. Wong, Pei-Yong Shi
  • Publication number: 20190120841
    Abstract: Embodiments of the invention are directed to stable full-length cDNA clones of a clinical, Asian lineage ZIKV strain. Certain embodiments of the invention are directed to high-throughput assays for ZIKV and dengue virus (DENV) diagnosis.
    Type: Application
    Filed: May 3, 2017
    Publication date: April 25, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Pei-Yong SHI, Chao SHAN, Xuping XIE
  • Patent number: 10240130
    Abstract: The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: March 26, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Xuping Xie, Chao Shan, Pei-Yong Shi
  • Publication number: 20180273913
    Abstract: The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV.
    Type: Application
    Filed: February 15, 2018
    Publication date: September 27, 2018
    Inventors: Xuping Xie, Chao Shan, Pei-Yong Shi
  • Publication number: 20180136225
    Abstract: Provided is a method of detecting the presence of an anti-Zika virus (ZIKV) antibody in a sample, including contacting a sample with a suspension having a plurality of microspheres wherein individual microspheres are conjugated to a peptide and the peptide includes a ZIKV peptide selected from the group including ZIKV NS1, ZIKV NS5, and ZIKV envelope protein, forming a first incubated suspension by incubating said sample with said suspension to permit binding of anti-ZIKV antibodies present in the sample to said microspheres, forming a second incubated suspension by contacting said first incubated suspension with an anti-ZIKV antibody detecting-reagent to permit binding of the anti-ZIKV antibody detecting reagent to said microspheres, removing from the second incubated suspension anti-ZIKV antibody detecting-reagent molecules that are not bound to said microspheres, and detecting the presence of anti-ZIKV antibody detecting-reagent molecules in the second incubated suspension.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 17, 2018
    Applicants: Health Research, Inc., The Board of Regents of The University Of Texas System
    Inventors: Susan J. WONG, Pei-Yong SHI
  • Publication number: 20150231226
    Abstract: The present invention discloses a method of eliciting an immune response and a method of vaccination comprising administration of a mutated flavivirus. The mutated flavivirus comprises at least one mutation in a nucleic acid sequence encoding for the non-structural protein 5 of the flavivirus sequence resulting in inactivation of the 2?O-methyltransferase.
    Type: Application
    Filed: September 23, 2013
    Publication date: August 20, 2015
    Applicants: Agency for Science, Technology and Research, Novartis AG, Beijing Institute of Microbiology and Epidemiology
    Inventors: Katja Fink, Pei-Yong Shi, Cheng Feng Qin
  • Publication number: 20110212986
    Abstract: The present invention relates to anti-flavivirus compounds, including lycorine and derivatives thereof, and their use in treating a subject infected by a flavivirus. The present invention also relates to the use of the anti-flavivirus compounds for the prophylaxis of flavivirus infection. The present invention further relates to a method of suppressing viral RNA synthesis of a flavivirus. Also described is a method of preparing an anti-flavivirus compound for use in the treatment or prophylaxis of flavivirus infection.
    Type: Application
    Filed: August 20, 2009
    Publication date: September 1, 2011
    Applicants: HEALTH RESEARCH, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Pei-Yong Shi, Francesc Puig-Basagoiti, Krzysztof W. Pankiewicz, Krzysztof Felczak, Liqiang Chen
  • Publication number: 20100279400
    Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.
    Type: Application
    Filed: April 1, 2008
    Publication date: November 4, 2010
    Inventors: Susan J. Wong, Pei-Yong Shi
  • Patent number: 7384785
    Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: June 10, 2008
    Assignee: Health Research, Inc.
    Inventors: Susan J. Wong, Pei-Yong Shi
  • Patent number: 7355033
    Abstract: The instant invention provides stable and novel lineage I WNV reverse genetics systems, and methods for making the reverse genetics systems, specifically, a fully-infectious lineage I WNV cDNA or replicon system engineered with one or more nucleotide sequences each encoding a reporter gene to be used in high throughput cell-based screening assays for the identification of novel antiflaviviral chemotherapeutics and/or vaccines effective to treat and/or immunize against infections by WNV and other emerging flaviviruses, such as, for example, JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV and MVEV. The present invention further provides methods of high throughput screening of antiflaviviral compounds or improved derivatives thereof using novel lineage I WNV reverse genetics systems and/or cell lines stably containing the reverse genetics systems.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: April 8, 2008
    Assignee: Health Research, Inc.
    Inventors: Pei-Yong Shi, Michael Lo, Mark Tilgner
  • Patent number: 7351547
    Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: April 1, 2008
    Assignee: Health Research, Inc.
    Inventors: Susan J. Wong, Pei-Yong Shi
  • Publication number: 20060115896
    Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.
    Type: Application
    Filed: May 4, 2004
    Publication date: June 1, 2006
    Inventors: Susan Wong, Pei-Yong Shi
  • Publication number: 20050058987
    Abstract: The instant invention provides stable and novel lineage I WNV reverse genetics systems, and methods for making the reverse genetics systems, specifically, a fully-infectious lineage I WNV cDNA or replicon system engineered with one or more nucleotide sequences each encoding a reporter gene to be used in high throughput cell-based screening assays for the identification of novel antiflaviviral chemotherapeutics and/or vaccines effective to treat and/or immunize against infections by WNV and other emerging flaviviruses, such as, for example, JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV and MVEV. The present invention further provides methods of high throughput screening of antiflaviviral compounds or improved derivatives thereof using novel lineage I WNV reverse genetics systems and/or cell lines stably containing the reverse genetics systems.
    Type: Application
    Filed: November 13, 2003
    Publication date: March 17, 2005
    Inventors: Pei-Yong Shi, Michael Lo, Mark Tilgner
  • Publication number: 20040197769
    Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.
    Type: Application
    Filed: October 31, 2003
    Publication date: October 7, 2004
    Inventors: Susan J. Wong, Pei-Yong Shi